ar-Turmerone is one of the main sesquiterpene ketones in turmeric rhizome oil and is already documented in AromaForge turmeric records at double-digit to major-component levels. Compared with many archive constituents, the evidence base here is relatively strong but still mostly preclinical: public studies support anti-inflammatory signaling effects in microglial models, neural stem-cell proliferation in rat work, and anticonvulsant or neuroprotective signals in animal and cell studies. Those findings make ar-turmerone a well-studied turmeric marker constituent, but not a basis for medical claims.
Chemical identity and composition
PubChem resolves ar-turmerone to CID 160512 with formula C15H20O and IUPAC name (6S)-2-methyl-6-(4-methylphenyl)hept-2-en-4-one. In the local archive it is a major turmeric ketone, recorded at 25.3% in Curcuma longa turmeric oil and 12.3% in one Curcuma caesia dark-turmeric profile.
Aroma and practical use
- Use the recorded warm spicy, woody, turmeric-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 microglial study reported that ar-turmerone suppressed A-beta-induced MMP-9, iNOS, COX-2, pro-inflammatory cytokines, MCP-1, and ROS in BV2 cells while inhibiting NF-kB, JNK, and p38 MAPK signaling.
A 2012 microglial study reported that ar-turmerone suppressed A-beta-induced MMP-9, iNOS, COX-2, pro-inflammatory cytokines, MCP-1, and ROS in BV2 cells while inhibiting NF-kB, JNK, and p38 MAPK signaling.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 stem-cell paper found that ar-turmerone increased rat neural stem-cell proliferation in vitro, promoted neuronal differentiation, and increased proliferating-cell signals in the adult rat subventricular zone and hippocampus after intracerebroventricular administration.
A 2014 stem-cell paper found that ar-turmerone increased rat neural stem-cell proliferation in vitro, promoted neuronal differentiation, and increased proliferating-cell signals in the adult rat subventricular zone and hippocampus after intracerebroventricular administration.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2017 mouse and BV2-cell neuroinflammation study reported that oral aromatic-turmerone attenuated LPS-induced memory disturbance, reduced microglial activation, and lowered inflammatory cytokine generation while acting through TLR4-dependent signaling.
A 2017 mouse and BV2-cell neuroinflammation study reported that oral aromatic-turmerone attenuated LPS-induced memory disturbance, reduced microglial activation, and lowered inflammatory cytokine generation while acting through TLR4-dependent signaling.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 seizure-model follow-up reported anticonvulsant activity for ar-turmerone in zebrafish and mouse models, brain penetration after intraperitoneal dosing, and no detectable mouse motor or balance impairment at a dose 500-fold above the effective 6-Hz dose.
A 2014 seizure-model follow-up reported anticonvulsant activity for ar-turmerone in zebrafish and mouse models, brain penetration after intraperitoneal dosing, and no detectable mouse motor or balance impairment at a dose 500-fold above the effective 6-Hz dose.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 neuron-culture study reported that ar-turmerone increased survival of cerebellar granule neurons under activity deprivation and reduced cleaved caspase-3 induction without measurably changing ROS or mitochondrial membrane potential.
A 2020 neuron-culture study reported that ar-turmerone increased survival of cerebellar granule neurons under activity deprivation and reduced cleaved caspase-3 induction without measurably changing ROS or mitochondrial membrane potential.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe strongest safety signal located in this pass was preclinical: one mouse study reported no observed motor or balance impairment even at a dose far above the effective anticonvulsant dose, but this is not a dermal-use or human safety standard.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
A 2022 turmeric-oil review described ar-turmerone as a major constituent within a generally favorable turmeric-oil safety literature, but the review is mixture-level and does not establish a constituent-specific topical limit or IFRA restriction for isolated ar-turmerone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
nf kb jnk p38 suppression
In amyloid-beta-stimulated BV2 microglia, ar-turmerone reduced inflammatory mediators while inhibiting NF-kB translocation plus JNK and p38 MAPK signaling.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
tlr4 dependent downstream modulation
An LPS neuroinflammation paper reported that aromatic-turmerone targeted TLR4-mediated downstream signaling and lowered inflammatory mediator release in BV2 cells and mice.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
neural stem cell proliferation signal
Full-text rat work reported dose-dependent increases in cultured neural stem-cell proliferation together with in vivo mobilization of proliferating cells from the subventricular zone and hippocampus after intracerebroventricular dosing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical trial specific to isolated ar-turmerone was verified in this pass.
- Most activity evidence remains neurologic, cellular, or animal-model work rather than topical-use evidence.
- No constituent-specific IFRA restriction or numeric dermal limit was located in the reviewed public sources.
- 2026-07-13 re-verification (worker c3): a follow-up targeted search for ar-turmerone (CAS 532-65-0) IFRA/dermal-limit data again found no constituent-specific numeric limit in the IFRA Standards library or supplier pages; dermal_limit_verified remains false.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.